The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee and Panel of Infectious Diseases Experts, would like to inform healthcare professionals on the interim authorisation of Pfizer-BioNTech COVID-19 Vaccine for active immunisation to prevent COVID-19 disease caused by SARS-CoV-2 virus in individuals 16 years of age and over. HSA has also issued a Dear Healthcare Professional Letter (DHCPL) to highlight to healthcare professionals the requirements on the safety monitoring of COVID-19 vaccine(s) that has been authorised for use in Singapore.

Please refer to the Dear Healthcare Professional Letter (DHCPL) below for more details:

1. Interim authorisation of Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) for active immunisation to prevent COVID-19 disease in Singapore
    
2. Monitoring the safety profile of COVID-19 vaccines